Asset
DERAMIOCEL
CAPRICOR THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03406780 | phase2 | completed | 2018-04-04 | 2020-03-10 | Capricor Inc. | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT05126758 | phase3 | active_not_recruiting | 2022-06-22 | 2025-06-18 | Capricor Inc. | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT04623671 | phase2 | completed | 2020-11-15 | 2022-02-04 | Capricor Inc. | Intravenous Infusion of CAP-1002 in Patients With COVID-19 |
| NCT04428476 | phase2 | active_not_recruiting | 2020-08-05 | 2022-02-16 | Capricor Inc. | Open-label Extension of the HOPE-2 Trial |
FDA applications (0)
This company has no applications containing this asset.